Skip to content

Strategies of Therapy With the Exoskeleton Robot ARMin

Strategies of Therapy With the Exoskeleton Robot ARMinMulti VIT-ARMin

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03100422
Acronym
MultiVIT-ARMin
Enrollment
18
Registered
2017-04-04
Start date
2017-05-01
Completion date
2018-10-31
Last updated
2020-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Brief summary

Neurological patients (e.g., after stroke) need long-term neurorehabilitation therapy of the arm with often limited, unsatisfactory outcome. Robots became a promising supplement or even alternative for neurorehabilitation training.

Detailed description

The exoskeleton robot ARMin was further developed and software components adapted accordingly to offer a unique intensified and patient-tailored robot-aided training of the arm. The goal is to enhance treatment efficacy to an extent that the improvement in motor function is meaningful for the individual patient. The study objective is to compare ARMin therapy and a form of conventional occupational therapy that involves both arms regarding change in motor function.

Interventions

DEVICEARMin

arm therapy robot

OTHEROccupational Therapy

bilateral arm training

Sponsors

Rehaklinik Zihlschlacht AG
CollaboratorOTHER
Swiss Federal Institute of Technology
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

Lots will be drawn that assign to either robotic therapy or occupational therapy

Intervention model description

randomized

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* \- Aged ≥18 years * Ischemic cerebral vascular accident (CVA, stroke) in the sub-acute phase (one to twelve weeks post-stroke) as verified by brain imaging (CT or MRI) * Inpatient at Rehaklinik Zihlschlacht, Switzerland * Decreased arm motor function in one arm with a FMA of 8 to 20 points (out of 66) * No excessive spasticity of the affected arm (modified Ashworth Scale mAS ≤3) as assessed by the physician * No serious medical or psychiatric disorder as assessed by the physician * No serious orthopaedic, rheumatologic or other disease restricting movements of the paretic arm as assessed by the physician * No clinically significant shoulder subluxation (palpation \<2 fingers) as assessed by the physician * No skin ulcerations at the paretic arm as assessed by the physician * Ability to communicate effectively with the examiner such that the validity of the patient's data could not be compromised as assessed by the physician * No history of cyber sickness (e.g., nausea when looking at a screen or playing computer games) as assessed by the physician * No pacemaker or other implanted electric device as verified by patient record * Bodyweight \<120 kg * No serious cognitive defects or aphasia preventing effective use of ARMin as assessed by the physician

Design outcomes

Primary

MeasureTime frameDescription
Fugl Meyer Assessment, upper extremity motor functionfrom baseline to day 3 post-trainingimpairment based clinical test

Secondary

MeasureTime frameDescription
ARMin assessment torquesfrom baseline to day 3 post-trainingtorques
ARMin assessment positionsfrom baseline to day 3 post-trainingpositions
ARMin assessment timefrom baseline to day 3 post-trainingtime
Motor Activity Logfrom baseline to day 3 post-trainingquestionnaire
handheld dynamometerfrom baseline to day 3 post-trainingisometric strength
Intrinsic Motivation Inventoryfrom baseline to day 3 post-trainingquestionnaire

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026